RxDoctor Payments Data

Keli Key

Psychiatric/Mental Health · Panama City, FLNPI 1487270476

Payments from drug & device makers

$466in general payments, 2019–2025

Across 24 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$154
  • AbbVie$102
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$67
  • E.r. Squibb & Sons, L.L.C.$46
  • Alkermes, Inc.$43
  • Otsuka America Pharmaceutical, Inc.$38
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$32369%
  • Education$14331%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$466 in reported general payments places this provider in the 40th percentile of 3,096 psychiatric/mental health providers in Florida.

See all psychiatric/mental health providers in Florida

Medicare billing

Part B allowed, 2024
$16,914
Medicare patients
81
Services billed
261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole201$321,528
Invega TrinzaPaliperidone Palmitate26$275,677
IngrezzaValbenazine Tosylate35$269,101
Invega SustennaPaliperidone Palmitate72$232,465
VraylarCariprazine Hcl94$144,354
AristadaAripiprazole Lauroxil26$89,204
CaplytaLumateperone Tosylate52$84,634
Abilify MaintenaAripiprazole32$81,036
TrintellixVortioxetine Hydrobromide81$34,723
Lurasidone Hcl133$26,607
ZyprexaOlanzapine16$19,236
LybalviOlanzapine/Samidorphan Malate11$18,913
FetzimaLevomilnacipran Hcl35$17,687
Aripiprazole238$15,640
Quetiapine Fumarate723$14,629

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$38$402,564233 claims
AbbVieVraylar, Fetzima$102$162,041129 claims
Alkermes, Inc.Aristada, Lybalvi$43$108,11737 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$67$84,63452 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 3,096 psychiatric/mental health providers in Florida.

Other psychiatric/mental health in Panama City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →